Teleflex Incorporated $TFX Shares Bought by Sepio Capital LP

Sepio Capital LP grew its position in Teleflex Incorporated (NYSE:TFX - Free Report) by 83.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,687 shares of the medical technology company's stock after acquiring an additional 3,034 shares during the period. Sepio Capital LP's holdings in Teleflex were worth $924,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in TFX. Millennium Management LLC boosted its holdings in Teleflex by 57.8% during the first quarter. Millennium Management LLC now owns 394,633 shares of the medical technology company's stock worth $54,534,000 after buying an additional 144,531 shares in the last quarter. Invenomic Capital Management LP boosted its holdings in Teleflex by 1,400.1% during the first quarter. Invenomic Capital Management LP now owns 344,732 shares of the medical technology company's stock worth $47,639,000 after buying an additional 321,751 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Teleflex by 7.4% during the first quarter. AQR Capital Management LLC now owns 292,523 shares of the medical technology company's stock worth $39,924,000 after buying an additional 20,225 shares in the last quarter. Calton & Associates Inc. purchased a new stake in Teleflex during the first quarter worth about $361,000. Finally, Vident Advisory LLC purchased a new stake in Teleflex during the first quarter worth about $1,223,000. Hedge funds and other institutional investors own 95.62% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Royal Bank Of Canada lifted their target price on shares of Teleflex from $130.00 to $135.00 and gave the stock a "sector perform" rating in a research report on Friday, August 1st. Wall Street Zen raised shares of Teleflex from a "buy" rating to a "strong-buy" rating in a research report on Sunday. Wells Fargo & Company dropped their price target on shares of Teleflex from $137.00 to $131.00 and set an "equal weight" rating for the company in a research report on Friday, August 1st. Finally, Mizuho upped their price target on shares of Teleflex from $130.00 to $135.00 and gave the stock a "neutral" rating in a research report on Friday, August 1st. One equities research analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Teleflex currently has an average rating of "Hold" and an average price target of $141.57.

Insiders Place Their Bets

In other news, Director Andrew A. Krakauer bought 1,000 shares of the firm's stock in a transaction dated Tuesday, August 5th. The stock was acquired at an average cost of $115.25 per share, for a total transaction of $115,250.00. Following the completion of the purchase, the director owned 7,192 shares of the company's stock, valued at $828,878. This trade represents a 16.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Liam Kelly bought 1,500 shares of the firm's stock in a transaction dated Tuesday, August 5th. The stock was purchased at an average price of $115.07 per share, with a total value of $172,605.00. Following the completion of the purchase, the chief executive officer directly owned 45,267 shares of the company's stock, valued at approximately $5,208,873.69. This trade represents a 3.43% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 5,500 shares of company stock valued at $633,590. Corporate insiders own 1.40% of the company's stock.

Teleflex Trading Up 0.1%

TFX traded up $0.07 during trading on Wednesday, hitting $130.30. 858,756 shares of the company's stock were exchanged, compared to its average volume of 542,622. The company has a current ratio of 2.41, a quick ratio of 1.44 and a debt-to-equity ratio of 0.42. Teleflex Incorporated has a 1 year low of $108.90 and a 1 year high of $249.90. The stock has a 50 day moving average price of $120.50 and a 200 day moving average price of $127.07. The firm has a market cap of $5.76 billion, a P/E ratio of 30.66, a price-to-earnings-growth ratio of 1.82 and a beta of 1.08.

Teleflex (NYSE:TFX - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.36 by $0.37. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The company had revenue of $780.90 million during the quarter, compared to the consensus estimate of $771.53 million. During the same period in the previous year, the firm earned $3.42 earnings per share. Teleflex's revenue for the quarter was up 4.2% on a year-over-year basis. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. As a group, analysts expect that Teleflex Incorporated will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, September 15th. Stockholders of record on Friday, August 15th will be paid a $0.34 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. Teleflex's dividend payout ratio is 32.00%.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.